Published in J Virol on August 01, 2001
Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol (2005) 2.94
Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) (2010) 2.48
Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med (2013) 2.02
Of the three tegument proteins that package mRNA in herpes simplex virions, one (VP22) transports the mRNA to uninfected cells for expression prior to viral infection. Proc Natl Acad Sci U S A (2002) 1.72
Conserved and divergent features of the structure and function of La and La-related proteins (LARPs). Biochim Biophys Acta (2010) 1.58
HBV pathogenesis in animal models: recent advances on the role of platelets. J Hepatol (2007) 1.20
Identification of Apurinic/apyrimidinic endonuclease 1 (APE1) as the endoribonuclease that cleaves c-myc mRNA. Nucleic Acids Res (2009) 1.20
Active lytic infection of human primary tonsillar B cells by KSHV and its noncytolytic control by activated CD4+ T cells. J Clin Invest (2011) 1.02
Cellular La protein shields nonsegmented negative-strand RNA viral leader RNA from RIG-I and enhances virus growth by diverse mechanisms. J Virol (2008) 0.98
Correlation of virus and host response markers with circulating immune complexes during acute and chronic woodchuck hepatitis virus infection. J Virol (2008) 0.84
Inhibition of human La protein by RNA interference downregulates hepatitis B virus mRNA in 2.2.15 cells. World J Gastroenterol (2004) 0.83
Anti-HBV Drugs: Progress, Unmet Needs, and New Hope. Viruses (2015) 0.83
A novel inhibitor of human La protein with anti-HBV activity discovered by structure-based virtual screening and in vitro evaluation. PLoS One (2012) 0.79
Viral DNA-Dependent Induction of Innate Immune Response to Hepatitis B Virus in Immortalized Mouse Hepatocytes. J Virol (2015) 0.77
Immunoregulation of hepatitis B virus infection--rationale and clinical application. Nagoya J Med Sci (2012) 0.76
Increase of Plasma IL-12/p40 Ratio Induced by the Combined Therapy of DNA Vaccine and Lamivudine Correlates with Sustained Viremia Control in CHB Carriers. Immune Netw (2009) 0.76
Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature (1979) 15.42
Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol (1999) 13.27
mRNA stability in mammalian cells. Microbiol Rev (1995) 8.78
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity (1996) 8.27
Coaxial stacking of helixes enhances binding of oligoribonucleotides and improves predictions of RNA folding. Proc Natl Acad Sci U S A (1994) 8.06
The structure and function of proteins involved in mammalian pre-mRNA splicing. Annu Rev Biochem (1996) 7.08
High-level hepatitis B virus replication in transgenic mice. J Virol (1995) 5.81
Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci U S A (1996) 5.53
An A + U-rich element RNA-binding factor regulates c-myc mRNA stability in vitro. Mol Cell Biol (1991) 4.31
3'-End processing of pre-mRNA in eukaryotes. FEMS Microbiol Rev (1999) 3.47
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A (1994) 3.34
The ends of the affair: capping and polyadenylation. Nat Struct Biol (2000) 3.31
Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science (1990) 3.26
Mechanisms of mRNA degradation in eukaryotes. Trends Biochem Sci (1994) 2.96
Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3' UTR and does not involve poly(A) tail shortening. EMBO J (1994) 2.70
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A (1996) 2.68
Control of mRNA stability by the virion host shutoff function of herpes simplex virus. J Virol (1989) 2.65
A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science (1985) 2.47
Cytotoxic T cells and viral hepatitis. J Clin Invest (1997) 2.46
Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol (1998) 2.06
To kill or to cure: options in host defense against viral infection. Curr Opin Immunol (1996) 2.06
Sequence-specific endonucleolytic cleavage and protection of mRNA in Xenopus and Drosophila. Genes Dev (1993) 1.82
Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci U S A (1995) 1.76
Properties of the exonuclease activity that degrades H4 histone mRNA. J Biol Chem (1987) 1.74
Purification and characterization of an estrogen-regulated Xenopus liver polysomal nuclease involved in the selective destabilization of albumin mRNA. J Biol Chem (1995) 1.62
Degradation of apolipoprotein II mRNA occurs via endonucleolytic cleavage at 5'-AAU-3'/5'-UAA-3' elements in single-stranded loop domains of the 3'-noncoding region. J Biol Chem (1989) 1.61
Endonucleolysis in the turnover of insulin-like growth factor II mRNA. J Biol Chem (1992) 1.45
Identification of an erythroid-enriched endoribonuclease activity involved in specific mRNA cleavage. EMBO J (2000) 1.44
Endonucleolytic cleavage of a maternal homeo box mRNA in Xenopus oocytes. Genes Dev (1990) 1.44
RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol (1998) 1.44
Cytokine-mediated control of viral infections. Virology (2000) 1.44
A bipartite model of 2-5A-dependent RNase L. J Biol Chem (1997) 1.42
The poly(A)-binding protein and an mRNA stability protein jointly regulate an endoribonuclease activity. Mol Cell Biol (2000) 1.39
Estrogen-induced ribonuclease activity in Xenopus liver. Biochemistry (1991) 1.37
Iron-responsive element-binding protein. Phosphorylation by protein kinase C. J Biol Chem (1993) 1.34
Vigilin binding selectively inhibits cleavage of the vitellogenin mRNA 3'-untranslated region by the mRNA endonuclease polysomal ribonuclease 1. Proc Natl Acad Sci U S A (2000) 1.33
Purification and characterization of a polysome-associated endoribonuclease that degrades c-myc mRNA in vitro. J Biol Chem (1998) 1.22
CTL access to tissue antigen is restricted in vivo. J Immunol (1994) 1.22
Transcriptional control of hepadnavirus gene expression. Curr Top Microbiol Immunol (1991) 1.21
Cleavage properties of an estrogen-regulated polysomal ribonuclease involved in the destabilization of albumin mRNA. Nucleic Acids Res (1997) 1.20
A human RNase E-like activity that cleaves RNA sequences involved in mRNA stability control. Proc Natl Acad Sci U S A (1995) 1.18
Characterization of mRNA endonucleases. Methods (1999) 1.16
La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J Virol (1999) 1.15
Iron regulatory factor--the conductor of cellular iron regulation. Blood Rev (1993) 1.09
ard-1: a human gene that reverses the effects of temperature-sensitive and deletion mutations in the Escherichia coli rne gene and encodes an activity producing RNase E-like cleavages. Proc Natl Acad Sci U S A (1994) 1.09
Specific endonucleolytic cleavage of IGF-II mRNAs. Biochem Biophys Res Commun (1991) 1.08
Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J Virol (1999) 1.06
ARD-1 cDNA from human cells encodes a site-specific single-strand endoribonuclease that functionally resembles Escherichia coli RNase E. J Biol Chem (1997) 0.98
Hormonal regulation of mRNA stability and RNA-protein interactions in the pituitary. J Mol Endocrinol (2000) 0.91
Posttranscriptional regulation of insulin-like growth factor II mRNA. Scand J Clin Lab Invest Suppl (1995) 0.86
Polyclonal antibodies against RNase L. Subcellular localization of this enzyme in mouse cells. J Biol Chem (1991) 0.81
Development of an in vitro mRNA degradation assay utilizing extracts from HIV-1- and SIV-infected cells. Virology (1996) 0.80
An RNasin-resistant ribonuclease selective for interleukin 2 mRNA. Nucleic Acids Res (1993) 0.80
Parallel acceleration of phosphoenolpyruvate carboxykinase mRNA degradation and increase in ribonuclease activity induced by insulin in cultured rat hepatocytes. Biol Chem (1998) 0.78
Purification of a RNA-binding protein from rat liver. Identification as ferritin L chain and determination of the RNA/protein binding characteristics. J Biol Chem (1997) 0.78
Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med (2001) 8.47
Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity (1996) 8.27
Viral clearance without destruction of infected cells during acute HBV infection. Science (1999) 6.78
High-level hepatitis B virus replication in transgenic mice. J Virol (1995) 5.81
Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol (2001) 5.81
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
Natural killer T cell activation inhibits hepatitis B virus replication in vivo. J Exp Med (2000) 3.93
Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology (1999) 3.73
The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med (1996) 3.60
Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest (1995) 3.47
HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol (1993) 3.42
The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med (1995) 3.34
Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci U S A (1994) 3.34
Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science (1990) 3.26
Expression of hepatitis B virus surface and core antigens: influences of pre-S and precore sequences. J Virol (1987) 3.16
Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med (1993) 3.06
Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest (1997) 2.99
Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol (1986) 2.94
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci U S A (2000) 2.70
Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci U S A (1996) 2.68
Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. J Clin Invest (1996) 2.65
Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol (2000) 2.65
Transmission of type B viral hepatitis to chimpanzees. J Infect Dis (1973) 2.51
Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol (1997) 2.50
HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med (1993) 2.49
Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. J Virol (2000) 2.49
Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol (1996) 2.47
A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science (1985) 2.47
Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology (2001) 2.38
Tumor necrosis factor alpha negatively regulates hepatitis B virus gene expression in transgenic mice. J Virol (1992) 2.25
Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science (1985) 2.18
Cytotoxic T lymphocyte response to a wild type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med (1994) 2.18
Immune pathogenesis of hepatocellular carcinoma. J Exp Med (1998) 2.11
Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest (1994) 2.10
Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest (1991) 2.08
Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in transgenic mice. J Virol (1998) 2.06
To kill or to cure: options in host defense against viral infection. Curr Opin Immunol (1996) 2.06
Class I-restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol (1994) 2.05
Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection. J Clin Invest (1996) 2.04
Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest (1996) 1.96
Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines. J Virol (1992) 1.94
Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J Virol (1994) 1.94
Intrahepatic, nucleocapsid antigen-specific T cells in chronic active hepatitis B. J Immunol (1987) 1.85
Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A (1994) 1.79
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice. J Virol (1994) 1.77
Posttranscriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci U S A (1995) 1.76
Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a posttranscriptional mechanism. J Virol (1993) 1.76
Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol (1993) 1.74
Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol (1986) 1.73
HBsAg retention sensitizes the hepatocyte to injury by physiological concentrations of interferon-gamma. Hepatology (1992) 1.68
Lymphocyte E rosette inhibitory factor: a regulatory serum lipoprotein. J Exp Med (1975) 1.66
Cytokine-induced viral purging--role in viral pathogenesis. Curr Opin Microbiol (1999) 1.55
Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol (1998) 1.51
Genetic regulation of the immune response to hepatitis B surface antigen (HBsAg). I. H-2 restriction of the murine humoral immune response to the a and d determinants of HBsAg. J Immunol (1982) 1.50
Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest (1997) 1.50
Cell mediated immune response to the hepatitis C virus. Curr Top Microbiol Immunol (2000) 1.48
Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J Exp Med (1999) 1.47
Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C. J Immunol (1999) 1.46
Cytokine-mediated control of viral infections. Virology (2000) 1.44
Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice. J Immunol (1997) 1.43
Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice. J Virol (2001) 1.43
The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol (1996) 1.40
Nitric oxide inhibits hepatitis B virus replication in the livers of transgenic mice. J Exp Med (2000) 1.35
Functional properties of lymphocyte subpopulations in hepatitis B virus infection. I. Suppressor cell control of T lymphocyte responsiveness. J Immunol (1981) 1.34
Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice. Cancer Res (1990) 1.34
Response of monkeys to immunization with cholera toxoid, toxin, and vaccine: reversion of cholera toxoid. J Infect Dis (1972) 1.32
Pathophysiologic effects of lethal and immunoregulatory doses of cholera enterotoxin in the mouse. J Immunol (1974) 1.31
Human T lymphocyte "E" rosette function. I. A process modulated by intracellular cyclic AMP. J Exp Med (1974) 1.31
Immunology and the liver. Hepatology (1991) 1.31
Immunopathology of hepatitis C. Springer Semin Immunopathol (1997) 1.30
Behçet's disease. Surv Ophthalmol (1982) 1.28
Nonoverlapping T and B cell determinants on an hepatitis B surface antigen pre-S(2) region synthetic peptide. J Exp Med (1986) 1.26
The modulating effect of cholera enterotoxin on the immune response. J Immunol (1974) 1.26
Nucleic acid vaccination primes hepatitis B virus surface antigen-specific cytotoxic T lymphocytes in nonresponder mice. J Virol (1995) 1.25
Functional characterization of cloned intrahepatic, hepatitis B virus nucleoprotein-specific helper T cell lines. J Immunol (1987) 1.25
Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice. J Immunol (1995) 1.23
CTL access to tissue antigen is restricted in vivo. J Immunol (1994) 1.22
Distinct H-2-linked regulation of T-cell responses to the pre-S and S regions of the same hepatitis B surface antigen polypeptide allows circumvention of nonresponsiveness to the S region. Proc Natl Acad Sci U S A (1985) 1.21
Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology (1997) 1.20